Allurion Technologies shares are trading higher after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock with a Buy rating and announced a $5 price target.
Portfolio Pulse from Benzinga Newsdesk
Allurion Technologies' shares surged following the announcement of its Virtual Care Suite's commercial availability in the US and a Buy rating with a $5 price target from Chardan Capital.
April 04, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allurion Technologies' stock is expected to experience a positive short-term impact due to the commercial launch of its Virtual Care Suite in the US and a favorable analyst rating with a $5 price target from Chardan Capital.
The commercial availability of Allurion Technologies' Virtual Care Suite in the US is a significant development, indicating potential growth and market penetration. Additionally, the Buy rating and $5 price target from Chardan Capital further validate the company's prospects, likely leading to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100